Batch documentation available to approved accounts
GLP-1 / Weight Management
Retatrutide
Triple receptor agonist hitting GLP-1, GIP, and glucagon receptors simultaneously. The compendium positions it as the most advanced GLP-1 class compound with early data showing the strongest body-weight reduction numbers in the class. Mechanism: GLP-1 appetite suppression; GIP fat metabolism; glucagon receptor activation accelerates visceral fat burning.
Research context
Advanced weight management; plateau after tirzepatide or semaglutide; visceral fat reduction.
Material information
- Grade
- Research Use Only (RUO)
- Format
- Lyophilized peptide material
- Purity
- Greater than 99%
- Appearance
- Lyophilized powder
Documentation
Batch-specific documentation may be available for approved account review. View documentation standards.
Regulatory status
For laboratory research use only. Not for human consumption, diagnosis, treatment, cure, or prevention of disease.
Restrictions
Research use only
This material is offered for research use only. Not for human or animal use. Not intended for clinical, diagnostic, therapeutic, veterinary, or personal use. PeptaPharma does not provide dosing, administration, or treatment guidance.
Related materials
Synthesized & tested in the United States.
PeptaPharma materials are produced and analytically tested in U.S. facilities. Batch-level documentation and Certificates of Analysis accompany each lot for approved-account review.